Prospective development of a patient-reported outcomes instrument for desmoid tumors or aggressive fibromatosis.

This is the first disease-specific PRO instrument developed for desmoid tumors. The instrument is available as an exploratory endpoint in clinical trials. This study highlights the feasibility and challenges of developing PRO instruments for rare diseases.